VEGFA and renal cell carcinoma: COMMD5 is poorly expressed in renal cell carcinoma; COMMD5 inhibits renal cell carcinoma proliferation, promotes differentiation, improves prognosis, enhances autophagic cell death, and inhibits tumor angiogenesis; The antitumor effect of COMMD5 is related to the inhibition of EGFR, ErbB receptors and VEGF (83, 84).